טוען...
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and anti-angiogenic drugs may improve the efficacy of ICB in mo...
שמור ב:
| הוצא לאור ב: | Sci Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7612153/ https://ncbi.nlm.nih.gov/pubmed/34380768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.abd1616 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|